CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +296 | $159.03 | $47K | 8,894 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −4,776 | $325.19 | $1.6M | 4,118 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −3,318 | $325.73 | $1.1M | 800 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −300 | $326.80 | $98K | 500 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −500 | $327.93 | $164K | 0 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −88,426 | 43,550 | ||
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −23,348 | 225,602 | ||
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −3,848 | 130,910 | ||
| 2025-09-09 | Wang Xiaodong Director | Gift | −148,096 | 5,006,674 | ||
| 2025-09-09 | Wang Lai Global Head of R&D | Sale 10b5-1 | −5,000 | $350.06 | $1.8M | 0 |
| 2025-09-05 | Sanders Corazon (Corsee) D. Director | Option exercise | +2,665 | $155.68 | $415K | 2,665 |
| 2025-09-05 | Sanders Corazon (Corsee) D. Director | Sale | −2,665 | $337.00 | $898K | 0 |
| 2025-09-05 | Sanders Corazon (Corsee) D. Director | Option exercise · Share Option (Right to Buy) | −34,645 | 0 | ||
| 2025-09-02 | Ball Titus B. Principal Accounting Officer | Sale | −122 | $326.76 | $40K | 0 |
| 2025-08-14 | Wu Xiaobin President and COO | Option exercise 10b5-1 | +30,756 | $155.68 | $4.8M | 30,756 |
| 2025-08-14 | Wu Xiaobin President and COO | Option exercise 10b5-1 | +9,180 | $159.03 | $1.5M | 39,936 |
| 2025-08-14 | Wu Xiaobin President and COO | Sale 10b5-1 | −400 | $300.86 | $120K | 39,536 |
| 2025-08-14 | Wu Xiaobin President and COO | Sale 10b5-1 | −5,800 | $302.04 | $1.8M | 33,736 |
| 2025-08-14 | Wu Xiaobin President and COO | Sale 10b5-1 | −6,965 | $303.31 | $2.1M | 26,771 |
| 2025-08-14 | Wu Xiaobin President and COO | Sale 10b5-1 | −500 | $304.19 | $152K | 26,271 |
Page 20 of 71 · 1,406 trades